Pfizer Plans to Shift Manufacturing to US Amid Threat of 25 Percent Tariffs

Pfizer CEO Albert Bourla announced that the pharmaceutical giant may shift its overseas manufacturing back to the United States in response to potential 25 percent tariffs on imported drugs. Speaking at the TD Cowen healthcare conference, Bourla emphasized that companies with established U.S. manufacturing networks are better positioned to adapt to such challenges.

Bourla stated, “We have the capabilities here, and the manufacturing sites are operating at good capacity right now.” He indicated that if tariffs are implemented, Pfizer would prioritize transferring production from its international facilities to its 10 U.S. manufacturing sites and two distribution centers.

The move comes as the Trump administration ramps up pressure on drug manufacturers to enhance domestic production. In a recent meeting with pharmaceutical CEOs, including those from Eli Lilly, discussions centered on tariff implications and manufacturing strategies. Eli Lilly announced plans to invest $27 billion in new U.S. plants, reflecting a broader industry trend toward bolstering local production capabilities.

As the regulatory landscape evolves, Pfizer's readiness to pivot its manufacturing strategy highlights its commitment to maintaining supply chain stability in the face of economic uncertainties. The potential for significant tariffs could reshape how pharmaceutical companies manage their global operations.